Literature DB >> 22902458

[A case of cancer of the pancreatic tail with disseminated carcinomatosis of the bone marrow].

Ken-ichi Nakamura1, Hiroshi Takamori, Osamu Nakahara, Yoshiaki Ikuta, Hideyuki Kuroki, Shigeki Nakagawa, Kosuke Mima, Hironao Okabe, Hidetoshi Nitta, Katsunori Imai, Akira Chikamoto, Koichi Doi, Takatoshi Ishiko, Toru Beppu, Ken-ichi Iyama, Hideo Baba.   

Abstract

Disseminated carcinomatosis of the bone marrow derived from solid cancer has a very poor prognosis, with disseminated intravascular coagulation(DIC). A 72-year-old man was admitted to our hospital after detection of a tumor in the pancreatic tail by CT imaging. Several images revealed that he suffered from cancer of the tail of the pancreas with multiple liver and bone metastases. Endoscopic ultra-sonography-guided fine needle aspiration detected adenocarcinoma cells from the tumor of the pancreatic tail. We also performed bone marrow aspiration, which confirmed adenocarcinoma cells in the bone marrow. We started to administer 1,000 mg/m2 of gemcitabine weekly. Laboratory data revealed that thrombocytopenia had occurred, and it developed into DIC after the first the administration of gemcitabine. In spite of the DIC state with thrombocytopenia, we were able to provide anticancer treatment using combination gemcitabine and S-1. He recovered from his DIC state, and the primary tumor was shrunk with a decrease of tumor markers after 2 courses of combination chemotherapy. Chemotherapy might be required for disseminated carcinomatosis of the bone marrow in order to promote tumor shrinkage and to prolonged expected survival, even if DIC was developed.

Entities:  

Mesh:

Year:  2012        PMID: 22902458

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  Disseminated carcinomatosis of the bone marrow from pancreatic cancer: a case report.

Authors:  Hiroki Namikawa; Yasuhiko Takemoto; Ayako Makuuchi; Masanori Kobayashi; Shigeki Kinuhata; Mina Morimura; Takashi Ikebe; Hiromu Tanaka; Taichi Shuto
Journal:  BMC Cancer       Date:  2016-10-13       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.